GALDERMA ACHIEVES FDA APPROVAL

Article

Galderma Laboratories has received FDA approval for Clobex (clobetasol propionate 0.05 percent) in a lotion formulation. The class I steroid prescription lotion is designed to control and treat steroid-responsive dermatoses, including moderate-to-severe psoriasis.

Related Videos
Related Content

Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies

October 1st 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies

October 1st 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies

October 1st 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.